SCHEMBL7185582

SCHEMBL7185582

Cc1cc(C)c(C(=O)Pc2ccc(-c3ccccc3)cc2)c(C)c1C.[LiH]

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
DHODH Q02127 6/20 0.35
PTGS1 P23219 2/20 0.34
ABCC4 O15439 1/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.34
HDAC8 Q9BY41 1/20 0.33
POLB P06746 1/20 0.33
CTDSP1 Q9GZU7 1/20 0.33
PTGS2 P35354 1/20 0.33
FFAR1 O14842 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MMP3 P08254 1/20 0.32
BCL2L1 Q07817 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175269 0.91 HSD17B10 (0.33) MAPTSMN1; SMN2LMNAGAA
Lithium SCHEMBL7185553 0.88 HSD17B10 (0.33) MAPTSMN1; SMN2LMNAGAA
SCHEMBL7178023 0.85 SMN1; SMN2 (0.41) MAPTSMN1; SMN2DHODHPTGS1ABCC4
SCHEMBL7179657 0.85 SRD5A2 (0.40) SMN1; SMN2DHODHPTGS1FFAR1
SCHEMBL7183519 0.84 KMT2A (0.32) SMN1; SMN2LMNAHTT
SCHEMBL7183770 0.81 FABP3 (0.40) MAPTSMN1; SMN2PTGS1ABCC4LMNA
SCHEMBL7188184 0.81 RXRB (0.42) MAPTSMN1; SMN2DHODHLMNA
SCHEMBL7186976 0.81 ALDH1A1 (0.35) MAPTSMN1; SMN2LMNAGAAPOLB
SCHEMBL7189338 0.80 KMT2A (0.35) SMN1; SMN2PTGS1LMNAGAAHTT
SCHEMBL7186821 0.79 LMNA (0.37) LMNAHTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885SMN1; SMN2 2939/4885DHODH 2946/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885SMN1; SMN2 3105/4885DHODH 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.